Various Aspects of a Gene Editing System—CRISPR–Cas9

Abstract

The discovery of clustered, regularly interspaced short palindromic repeats (CRISPR) and their cooperation with CRISPR-associated (Cas) genes is one of the greatest advances of the century and has marked their application as a powerful genome engineering tool. The CRISPR–Cas system was discovered as a part of the adaptive immune system in bacteria and archaea to defend from plasmids and phages. CRISPR has been found to be an advanced alternative to zinc-finger nucleases (ZFN) and transcription activator-like effector nucleases (TALEN) for gene editing and regulation, as the CRISPR–Cas9 protein remains the same for various gene targets and just a short guide RNA sequence needs to be altered to redirect the site-specific cleavage. Due to its high efficiency and precision, the Cas9 protein derived from the type II CRISPR system has been found to have applications in many fields of science. Although CRISPR–Cas9 allows easy genome editing and has a number of benefits, we should not ignore the important ethical and biosafety issues. Moreover, any tool that has great potential and offers significant capabilities carries a level of risk of being used for non-legal purposes. In this review, we present a brief history and mechanism of the CRISPR–Cas9 system. We also describe on the applications of this technology in gene regulation and genome editing; the treatment of cancer and other diseases; and limitations and concerns of the use of CRISPR–Cas9.

Advances in identifying GM plants: toward the routine detection of ‘hidden’ and ‘new’ GMOs

“…Additionally, targeted sequence sizes differentiate ZFN, TALEN and CRISPR-Cas techniques (see Fig. 1 for more details; Janik et al, 2020), as also shown for example, for the length of the artificial TALEN 10 cleaving site (half-site 14-20 nt -FokI site 14-24 nt -half-site 14-20 nt) (Ahmad et al, 2020;Khalil, 2020). Moreover, specific sequences can be found near and at the enzyme cleavage and homologous sequence sites (e.g.…”

Clinical applications of mesenchymal stromal cell-based therapies for pulmonary diseases: An Update and Concise Review

“…In addition to applications in tissue engineering, to enhance their therapeutic efficacy, developing a cellular therapy using MSCs as attractive delivery vectors is the ultimate goal of this area of research. Genetic engineering methods to modify MSCs can be classified as those using viral transduction, nonviral transfection, or genome editing tools and techniques to overexpress therapeutic proteins that complement their innate properties (Figure 3) [43][44][45][46]. A growing body of evidence indicates that the paracrine, homing, immunomodulatory, anti-inflammatory, and tissue repair properties of MSCs can be strengthened through genetic modification [47].…”

CRISPR-Cas and Its Wide-Ranging Applications: From Human Genome Editing to Environmental Implications, Technical Limitations, Hazards and Bioethical Issues

“…The manager went on to remark that “the steep drop in the costs of genomic sequencing and gene editing toolkits, along with the increasing accessibility of this technology”, has engendered even greater opportunity to experiment with genetic modifications. In addition, this convergence of low cost and high availability means that applications for gene editing, both positive and negative, could arise from individuals or state entities that operate outside the scope and supervision of the traditional scientific community [ 193 ]. The ethical implications of such remarks are quite startling, in light of the potential such techniques indisputably possess.…”